Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

Daniel A Rodrigues; Fernanda S Sagrillo; Carlos A M Fraga

doi:10.3390/ph12020069

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

Pharmaceuticals (Basel). 2019 May 6;12(2):69. doi: 10.3390/ph12020069.

Authors

Daniel A Rodrigues^{1

2}, Fernanda S Sagrillo³, Carlos A M Fraga^{4

5}

Affiliations

¹ Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, Rio de Janeiro, RJ 21941-902, Brazil. dar.go.qfm@gmail.com.
² Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-909, Brazil. dar.go.qfm@gmail.com.
³ Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, Rio de Janeiro, RJ 21941-902, Brazil. fefa_uff@yahoo.com.br.
⁴ Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, Rio de Janeiro, RJ 21941-902, Brazil. cmfraga@ccsdecania.ufrj.br.
⁵ Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-909, Brazil. cmfraga@ccsdecania.ufrj.br.

Abstract

Duvelisib (Copiktra^®) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib has also been approved under accelerated track for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. In this review, we provide a series of information about duvelisib, such as the development of clinical trials for LLC/SLL and FL and the steps used for its synthesis.

Keywords: Copiktra; FDA; approved drugs; cancer; duvelisib; phosphoinositide 3-kinases.

Abstract

Grants and funding